Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA; XaNADU-ACS INVESTIGATORS. Alexander JH, et al. Among authors: bovill eg. J Thromb Haemost. 2005 Mar;3(3):439-47. doi: 10.1111/j.1538-7836.2004.01081.x. J Thromb Haemost. 2005. PMID: 15748230 Free article. Clinical Trial.
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA. Dyke CK, et al. Among authors: bovill eg. Circulation. 2002 May 21;105(20):2385-91. doi: 10.1161/01.cir.0000016351.12759.52. Circulation. 2002. PMID: 12021225 Clinical Trial.
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Saint-Jacques H, Chetcuti S, Burton JR, Buergler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW, Harrington RA; XaNADU-PCI PILOT Investigators. Alexander JH, et al. Among authors: bovill eg. J Thromb Haemost. 2004 Feb;2(2):234-41. doi: 10.1111/j.1538-7933.2004.00594.x. J Thromb Haemost. 2004. PMID: 14995984 Free article. Clinical Trial.
Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill EG. Granger CB, et al. Among authors: bovill eg. J Am Coll Cardiol. 1998 Mar 1;31(3):497-505. doi: 10.1016/s0735-1097(97)00539-1. J Am Coll Cardiol. 1998. PMID: 9502626 Free article. Clinical Trial.
Pathobiology of thrombin in acute coronary syndromes.
Becker RC, Bovill EG, Seghatchian MJ, Samama MM. Becker RC, et al. Among authors: bovill eg. Am Heart J. 1998 Oct;136(4 Pt 2 Su):S19-31. doi: 10.1053/hj.1998.v136.93435. Am Heart J. 1998. PMID: 9778085 Review. No abstract available.
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Zabel KM, Granger CB, Becker RC, Bovill EG, Hirsh J, Aylward PE, Topol EJ, Califf RM. Zabel KM, et al. Among authors: bovill eg. Am Heart J. 1998 Nov;136(5):868-76. doi: 10.1016/s0002-8703(98)70133-4. Am Heart J. 1998. PMID: 9812083 Clinical Trial.
186 results